Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Urticaria 1Sarcoma 1Prostatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Mastocytosis, Systemic 1Mastocytosis 1Histiocytoma, Malignant Fibrous 1Colorectal Neoplasms 1Angioedemas, Hereditary 1Angioedema 1Adenoma, Islet Cell 1

Interventions

Doxorubicin 19Radiotherapy 10Ifosfamide 10apatinib 9anlotinib 8Cyclophosphamide 8camrelizumab 7Vincristine 5Dactinomycin 5toripalimab 3Trabectedin 3Radiation Dose Hypofractionation 3Etoposide 3Docetaxel 3ribociclib 2brostallicin 2Topotecan 2Thalidomide 2Temozolomide 2Sorafenib 2Oncolytic Virotherapy 2Nivolumab 2Neoadjuvant Therapy 2Melphalan 2Magnetic Resonance Spectroscopy 2Irinotecan 2Ipilimumab 2Immune Checkpoint Inhibitors 2Gene Expression Profiling 2Gemcitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Sarcoma × Phlebotomy × Clear all
NCT03946943 2019-07-10

Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma

The First Hospital of Jilin University

Phase 2 Unknown
25 enrolled
Sarcoma

Sarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡